Skip to main content
. 2024 Oct 23;12(4):817–831. doi: 10.1007/s40487-024-00309-z

Table 2.

Severity of potential immune adverse events (N = 15)

Adverse event NCI CTCAE grade Total
1 2 3
Back pain 1 1
Diarrhea 1 1 2
Dyspepsia 0 1 1
Rash 1 1
Elevated amylase levels 0 1 1
Elevated liver enzyme levels 1 1 1 3
Elevated creatinine levels 0 1 1
Hypothyroidism 1 1 2
Hyperthyroidism 1 1 2
Arthralgia 0 0 1 1

NA not applicable, NCI CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events